USA - NASDAQ:KLTO - US49876K1034 - Common Stock
The current stock price of KLTO is 0.5246 USD. In the past month the price increased by 8.25%. In the past year, price increased by 25.2%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.49 | 401.96B | ||
| AMGN | AMGEN INC | 13.39 | 157.25B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 146.27B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.93 | 108.30B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 62.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.34 | 69.37B | ||
| ARGX | ARGENX SE - ADR | 90.81 | 51.50B | ||
| INSM | INSMED INC | N/A | 34.94B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.11 | 34.80B | ||
| NTRA | NATERA INC | N/A | 26.02B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.25B | ||
| BIIB | BIOGEN INC | 9.31 | 21.86B |
Klotho Neurosciences, Inc. engages in the provision of new therapies to treat neurodegenerative diseases. The company is headquartered in Omaha, Nebraska and currently employs 3 full-time employees. The company went IPO on 2022-04-29. The firm's licensed platforms, namely, a generic drug portfolio and a biosimilar biologics platform uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Its primary focus is the advancement of a sustainable portfolio of cell and gene therapy product candidates for age-associated neurologic diseases, both rare orphan diseases and diseases in larger patient populations. The firm's two lead gene therapy product candidates are KLTO-101 (AAV9-CMV-sKL) for the treatment or prevention of Alzheimer’s disease, and KLTO-202 (AAVmyo-Des-sKL) gene therapy product for the treatment and prevention of Lou Gehrig’s disease (amyotrophic lateral sclerosis).
KLOTHO NEUROSCIENCES INC
13576 Walnut Street, Suite A
Omaha NEBRASKA US
Employees: 3
Phone: 18339316330
Klotho Neurosciences, Inc. engages in the provision of new therapies to treat neurodegenerative diseases. The company is headquartered in Omaha, Nebraska and currently employs 3 full-time employees. The company went IPO on 2022-04-29. The firm's licensed platforms, namely, a generic drug portfolio and a biosimilar biologics platform uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Its primary focus is the advancement of a sustainable portfolio of cell and gene therapy product candidates for age-associated neurologic diseases, both rare orphan diseases and diseases in larger patient populations. The firm's two lead gene therapy product candidates are KLTO-101 (AAV9-CMV-sKL) for the treatment or prevention of Alzheimer’s disease, and KLTO-202 (AAVmyo-Des-sKL) gene therapy product for the treatment and prevention of Lou Gehrig’s disease (amyotrophic lateral sclerosis).
The current stock price of KLTO is 0.5246 USD. The price decreased by -3.71% in the last trading session.
KLTO does not pay a dividend.
KLTO has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
KLOTHO NEUROSCIENCES INC (KLTO) currently has 3 employees.
You can find the ownership structure of KLOTHO NEUROSCIENCES INC (KLTO) on the Ownership tab.
ChartMill assigns a technical rating of 1 / 10 to KLTO. When comparing the yearly performance of all stocks, KLTO is a bad performer in the overall market: 82.18% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to KLTO. No worries on liquidiy or solvency for KLTO as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months KLTO reported a non-GAAP Earnings per Share(EPS) of -0.45. The EPS decreased by -1684.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -104.68% | ||
| ROE | -106.6% | ||
| Debt/Equity | 0 |